ArticleFrontiers in immunology2021
Cytokine Imprint in Preeclampsia.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Association of LEPTIN and other inflammatory markers with preeclampsia: A systematic review.Frontiers in pharmacology · 2022Pooled it
- The Immuno-Cardiovascular Storm of Pre-Eclampsia: Cytokine-Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability.Comprehensive Physiology · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Article
- Dysregulation of Treg/Th17 Balance and Intracellular Expression of IL-21 and IL-22 in the Pathogenesis of Gestational Hypertension.Journal of clinical medicine · 2025Article
- Profiling Cytokines According to the Presence or Absence of Small-for-Gestational Age Using Amniotic Fluid Retrieved During Cesarean Section From Pregnant Women With Early-Onset Preeclampsia.Journal of Korean medical science · 2025Article
- PD1+ T Regulatory Cells Are Not Sufficient to Protect from Gestational Hypertension.International journal of molecular sciences · 2025Article
- Early prediction of preeclampsia using the first trimester vaginal microbiome.bioRxiv : the preprint server for biology · 2024Article
- Circulating Immune Cells from Early- and Late-onset Pre-eclampsia Displays Distinct Profiles with Differential Impact on Endothelial Activation.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Research Progress on Extracellular Matrix Involved in the Development of Preeclampsia.Current protein & peptide science · 2024Review
- The association of a panel of circulating markers with hypertensive disorders of pregnancy: the jury is still out.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Mitochondrial-targeted antioxidant attenuates preeclampsia-like phenotypes induced by syncytiotrophoblast-specific Gαq signaling.Science advances · 2023Article
- Machine learning-based protein signatures for differentiating hypertensive disorders of pregnancy.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Article
- First-trimester plasma extracellular heat shock proteins levels and risk of preeclampsia.Journal of cellular and molecular medicine · 2023Article
- Distinct cytokine profiles in patients with preeclampsia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Setting a stage: Inflammation during preeclampsia and postpartum.Frontiers in physiology · 2023Review
- Modulation of vagal activity may help reduce neurodevelopmental damage in the offspring of mothers with pre-eclampsia.Frontiers in immunology · 2023Article
- Effects of Maternal Pre-Pregnancy BMI and Gestational Weight Gain on the Development of Preeclampsia and Its Phenotypes: A Prospective Cohort Study in China.Journal of clinical medicine · 2022Article
- Distinct gene expression patterns for CD14++ and CD16++ monocytes in preeclampsia.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hallmark of preeclampsia (PE) is a shift toward persistent inflammatory response, accompanied by endothelial dysfunction. The driving forces in PE are proinflammatory cytokine and growth factors, in parallel with reduced functionality of anti-inflammatory effectors, like regulatory T cells are observed. Unfortunately, no conclusive mechanism underlying preeclampsia has been identified. For this reason, research on preeclampsia is needed to provide a state of the art understanding of the pathophysiology, identification of new diagnostics tools and the development of targeted therapies. The 68 patients were divided into three groups: gestational hypertension (GH) group (n = 19) and PE group (n = 28) and a control group (n = 21). We have tested a set of 53 cytokines, chemokines and growth factors in preeclampsia and gestational hypertension, and then compared them with normal pregnancies. Using a diagnostic test assessment characteristic parameters (IL-22, MDC/CCL22, IL-2/IL-4 ratio) have been identified and cut-off values have been proposed to diagnose preeclampsia. All parameters had high negative or positive predictive values, above 80%. In conclusion, we have proposed a potential set of immune parameters to diagnose preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.